| Clinical outcome after rectal replacement with side-to-end, colon-J-pouch, or straight colorectal anastomosis following total mesorectal excision: a Swiss prospective … WR Marti, G Curti, H Wehrli, F Grieder, M Graf, B Gloor, M Zuber, ... Annals of surgery 269 (5), 827-835, 2019 | 63 | 2019 |
| A systematic review and meta‐analysis on the influence of biological implant surface coatings on periimplant bone formation G Jenny, J Jauernik, S Bierbaum, M Bigler, KW Grätz, M Rücker, ... Journal of Biomedical Materials Research Part A 104 (11), 2898-2910, 2016 | 49 | 2016 |
| SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2 … C Rochlitz, M Bigler, R von Moos, J Bernhard, K Matter-Walstra, A Wicki, ... BMC cancer 16, 1-8, 2016 | 45 | 2016 |
| The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with … B Drexler, JR Passweg, A Tzankov, M Bigler, APA Theocharides, ... Haematologica 104 (4), 710, 2018 | 36 | 2018 |
| Quality of life after total mesorectal excision and rectal replacement: comparing side-to-end, colon J-pouch and straight colorectal reconstruction in a randomized, phase III … K Ribi, WR Marti, J Bernhard, F Grieder, M Graf, B Gloor, G Curti, M Zuber, ... Annals of surgical oncology 26, 3568-3576, 2019 | 25 | 2019 |
| Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10) BC Pestalozzi, C Tausch, KJ Dedes, C Rochlitz, S Zimmermann, ... BMC cancer 17, 1-10, 2017 | 20 | 2017 |
| SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with … C Rochlitz, R von Moos, M Bigler, K Zaman, S Anchisi, M Küng, KJ Na, ... Journal of Clinical Oncology 32 (15_suppl), 518-518, 2014 | 16 | 2014 |
| Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients M Zweifel, B Thürlimann, S Riniker, P Weder, R von Moos, O Pagani, ... Endocrine connections 6 (7), 549-556, 2017 | 15 | 2017 |
| NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma B Jeker, U Novak, B Mansouri Taleghani, GM Baerlocher, K Seipel, ... Bone marrow transplantation 53 (2), 175-179, 2018 | 11 | 2018 |
| External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26 E Herrmann, D Naehrig, M Sassowsky, M Bigler, J Buijsen, I Ciernik, ... Radiation oncology 12, 1-9, 2017 | 7 | 2017 |
| Effects of the sympathicomimetic agonist mirabegron on disease course, mutant allele burden, marrow fibrosis, and nestin positive stem cell niche in patients with JAK2-mutated … B Drexler, J Passweg, M Bigler, APA Theocharides, N Cantoni, P Keller, ... Blood 128 (22), 3108, 2016 | 6 | 2016 |
| Abstract P5-14-05: Phase 1 evaluation of the androgen receptor modulator CR1447 in patients with advanced breast cancer (SAKK 21/12) W Schoenfeld, M Zweifel, B Thuerlimann, S Riniker, P Weder, R von Moos, ... Cancer Research 76 (4_Supplement), P5-14-05-P5-14-05, 2016 | 3 | 2016 |
| Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2 … K Matter-Walstra, M Bigler, M Schwenkglenks, D Bärtschi, J Brechbühl, ... SABCS. San Antonio USA, 2014 | 2 | 2014 |
| 1971 A correlative study of Ki67 and two multigene RNA expression signatures in operable ER-positive postmenopausal breast cancer (SAKK 26/10) R Jaggi, Z Varga, M Bigler, V Bize, MB Eduardo, S Berardi, F Chiesa, ... European Journal of Cancer 51, S324, 2015 | 1 | 2015 |
| 1943 Adjuvant treatment recommendations for ER+ early breast cancer patients by Swiss tumor boards (SAKK 26/10) BC Pestalozzi, C Tausch, KJ Dedes, C Rochlitz, S Zimmermann, ... European Journal of Cancer 51, S313, 2015 | 1 | 2015 |
| Abstract P1-10-06: Health economic evaluation of: Bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in … KW Matter-Walstra, M Bigler, M Schwenkglenks, D Bertschi, J Brechbühl, ... Cancer Research 75 (9_Supplement), P1-10-06-P1-10-06, 2015 | 1 | 2015 |
| Khalil Zaman6, Sandro Anchisi7, Marc Küng8, Kyung-Jae Na2, 9, Daniela Bärtschi2, Markus Borner10, Tamara Rordorf11, Daniel Rauch12, Andreas Müller13, Thomas Ruhstaller14 … C Rochlitz, M Bigler, R von Moos, J Bernhard, K Matter-Walstra, A Wicki | | 2016 |
| External Beam Radiation Therapy for Unresectable Hepatocellular Carcinoma: An International Multicenter Phase I Trial, SAKK 77/07 E Herrmann, D Naehrig, J Buijsen, IF Ciernik, DR Zwahlen, AF Pellanda, ... International Journal of Radiation Oncology, Biology, Physics 93 (3), E152, 2015 | | 2015 |
